Le Lézard
Classified in: Health, Science and technology
Subjects: Stock Sale/Buyback, Business Update

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 401,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

The stock options were granted on October 18, 2023 at an exercise price of $1.77 per share, which is equal to the closing price of Geron common stock on the date of grant. Stock options representing an aggregate of 396,000 shares have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment for the respective employees and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. Stock options representing an aggregate of 5,220 shares have a 10-year term and vest in full upon achievement of a certain regulatory milestone, subject to continued employment with Geron through the applicable vesting date. All of the stock options were granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Geron's 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.

About Geron

Geron is a late-stage clinical biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class investigational telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. The New Drug Application (NDA) for imetelstat in lower risk myelodysplastic syndromes (LR MDS), based on the results from the Phase 3 IMerge clinical trial, is currently under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024. In addition, an MAA is now under regulatory review by the European Committee for Medicinal Products for Human Use (CHMP) for the same proposed indication. Furthermore, Geron currently has an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis (MF). To learn more, visit www.geron.com or follow us on LinkedIn.


These press releases may also interest you

12 oct 2024
NASA will provide live coverage of prelaunch and launch activities for Europa Clipper, the agency's mission to explore Jupiter's icy moon Europa. NASA now is targeting launch no earlier than 12:06 p.m. EDT, Monday, Oct. 14, on a SpaceX Falcon Heavy...

12 oct 2024
A news report from english.shanghai.gov.cn:  A total of 750 vehicles have been delivered by SAIC Motor Corp Ltd to transport dignitaries attending the upcoming seventh China International Import Expo (CIIE) during a...

12 oct 2024
Here TV, the premier destination for LGBTQ+ content, proudly announces the return of Guys Like You for an...

12 oct 2024
Flood waters in the aftermath of hurricane Helene left significant property and equipment losses for Joseph Camerieri and his home and business. Only recently did those waters recede to where cleanup can occur. "I'm not a quitter," said Camerieri in...

12 oct 2024
Eulerity, the industry-leading platform for multi-location marketing, just announced strategic partnerships with several prominent brands. Famous Brands International, the parent company of Mrs. Fields and TCBY, along with HealthSource Chiropractic,...

12 oct 2024
GITEX GLOBAL, the world's largest tech and startup event, takes centre stage in the UAE next week with this year's 44th edition destined to redefine the world's digital economy and AI ecosystem....



News published on and distributed by: